ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RCEL vs MDXG // EV/EBITDA & P/E VALUATION

Avita Medical Inc. (NASDAQ) VS. MiMedx Group Inc (NASDAQ) • 15-METRIC TALLY: RCEL 1 — MDXG 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RCEL VS. MDXG) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RCEL MDXG SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 82.10% 82.60% -0.50 MDXG /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 47.20% -82.20 MDXG /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 6.7x — TIE /valuation <GO>
Free Cash Flow Yield -6.23% 12.77% -19.00 MDXG /fcf-yield <GO>
Operating Margin -59.40% 15.30% -74.70 MDXG /operating-margins <GO>
Net Profit Margin -60.00% 11.60% -71.60 MDXG /net-margins <GO>
Revenue Growth (YoY) 11.50% 20.00% -8.50 MDXG /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 6.45 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 9/9 -5.00 MDXG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 66.2 32.9 +33.28 RCEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 10.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $516.8M $579.3M -$62.5M MDXG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RCEL REV MDXG REV RCEL GROSS % MDXG GROSS % RCEL FCF MDXG FCF
FY 2025 $71.6M $418.6M 82.1% 82.6% -$32.2M $74.0M
FY 2024 $64.3M $348.9M 85.8% 82.8% -$58.1M $66.2M
FY 2023 $50.1M $321.5M — — -$38.0M $26.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RCEL // BETA —
MDXG // BETA —